Multiple myeloma

Kenneth C. Anderson; Melissa Alsina; William Bensinger; J. Sybil Biermann; Asher Chanan-Khan; Adam D. Cohen; Steven Devine; Benjamin Djulbegovic; Cristina Gasparetto; Carol Ann Huff; Madan Jagasia; Bruno C. Medeiros; Ruby Meredith; Noopur Raje; Jeffrey Schriber; Seema Singhal; George Somlo; Keith Stockerl-Goldstein; Guido Tricot; Julie M. Vose; Donna Weber; Joachim Yahalom; Furhan Yunus

doi:10.6004/jnccn.2009.0061

Multiple myeloma

Kenneth C. Anderson, Melissa Alsina, William Bensinger, J. Sybil Biermann, Asher Chanan-Khan, Adam D. Cohen, Steven Devine, Benjamin Djulbegovic, Cristina Gasparetto, Carol Ann Huff, Madan Jagasia, Bruno C. Medeiros, Ruby Meredith, Noopur Raje, Jeffrey Schriber, Seema Singhal, George Somlo, Keith Stockerl-Goldstein, Guido Tricot, Julie M. VoseDonna Weber, Joachim Yahalom, Furhan Yunus

Research output: Contribution to journal › Review article › peer-review

76 Scopus citations

Abstract

Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

Original language	English
Pages (from-to)	908-942
Number of pages	35
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	7
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2009.0061
State	Published - Oct 2009

Keywords

Bisphosphonates
C-reactive protein
Combination chemotherapy
Cytogenetics
Immunomodulatory drugs
Multiple myeloma
NCCN Clinical Practice Guidelines
Novel therapies
Primary amyloidosis
Proteasome inhibitor
Stem cell transplant
Supportive therapies
Waldenström's monoclonal protein

Access to Document

10.6004/jnccn.2009.0061

Cite this

Anderson, K. C., Alsina, M., Bensinger, W., Biermann, J. S., Chanan-Khan, A., Cohen, A. D., Devine, S., Djulbegovic, B., Gasparetto, C., Huff, C. A., Jagasia, M., Medeiros, B. C., Meredith, R., Raje, N., Schriber, J., Singhal, S., Somlo, G., Stockerl-Goldstein, K., Tricot, G., ... Yunus, F. (2009). Multiple myeloma. JNCCN Journal of the National Comprehensive Cancer Network, 7(9), 908-942. https://doi.org/10.6004/jnccn.2009.0061

@article{2b088f0502824e27af76efa2c2518c7b,

title = "Multiple myeloma",

abstract = "Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.",

keywords = "Bisphosphonates, C-reactive protein, Combination chemotherapy, Cytogenetics, Immunomodulatory drugs, Multiple myeloma, NCCN Clinical Practice Guidelines, Novel therapies, Primary amyloidosis, Proteasome inhibitor, Stem cell transplant, Supportive therapies, Waldenstr{\"o}m's monoclonal protein",

author = "Anderson, {Kenneth C.} and Melissa Alsina and William Bensinger and Biermann, {J. Sybil} and Asher Chanan-Khan and Cohen, {Adam D.} and Steven Devine and Benjamin Djulbegovic and Cristina Gasparetto and Huff, {Carol Ann} and Madan Jagasia and Medeiros, {Bruno C.} and Ruby Meredith and Noopur Raje and Jeffrey Schriber and Seema Singhal and George Somlo and Keith Stockerl-Goldstein and Guido Tricot and Vose, {Julie M.} and Donna Weber and Joachim Yahalom and Furhan Yunus",

year = "2009",

month = oct,

doi = "10.6004/jnccn.2009.0061",

language = "English",

volume = "7",

pages = "908--942",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "9",

}

Anderson, KC, Alsina, M, Bensinger, W, Biermann, JS, Chanan-Khan, A, Cohen, AD, Devine, S, Djulbegovic, B, Gasparetto, C, Huff, CA, Jagasia, M, Medeiros, BC, Meredith, R, Raje, N, Schriber, J, Singhal, S, Somlo, G, Stockerl-Goldstein, K, Tricot, G, Vose, JM, Weber, D, Yahalom, J & Yunus, F 2009, 'Multiple myeloma', JNCCN Journal of the National Comprehensive Cancer Network, vol. 7, no. 9, pp. 908-942. https://doi.org/10.6004/jnccn.2009.0061

TY - JOUR

T1 - Multiple myeloma

AU - Anderson, Kenneth C.

AU - Alsina, Melissa

AU - Bensinger, William

AU - Biermann, J. Sybil

AU - Chanan-Khan, Asher

AU - Cohen, Adam D.

AU - Devine, Steven

AU - Djulbegovic, Benjamin

AU - Gasparetto, Cristina

AU - Huff, Carol Ann

AU - Jagasia, Madan

AU - Medeiros, Bruno C.

AU - Meredith, Ruby

AU - Raje, Noopur

AU - Schriber, Jeffrey

AU - Singhal, Seema

AU - Somlo, George

AU - Stockerl-Goldstein, Keith

AU - Tricot, Guido

AU - Vose, Julie M.

AU - Weber, Donna

AU - Yahalom, Joachim

AU - Yunus, Furhan

PY - 2009/10

Y1 - 2009/10

N2 - Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

AB - Although MM is sensitive to both chemotherapy and radiation therapy, it remains incurable. However, treatment algorithms (based on published data and clinical experience) can be developed to optimize therapy, which include not only therapy for the underlying disease but also supportive therapy to enhance quality of life. Because myeloma is incurable, these guidelines prominently identify the clinical settings appropriate for treating patients enrolled in clinical research protocols.

KW - Bisphosphonates

KW - C-reactive protein

KW - Combination chemotherapy

KW - Cytogenetics

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - NCCN Clinical Practice Guidelines

KW - Novel therapies

KW - Primary amyloidosis

KW - Proteasome inhibitor

KW - Stem cell transplant

KW - Supportive therapies

KW - Waldenström's monoclonal protein

UR - http://www.scopus.com/inward/record.url?scp=72149104327&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2009.0061

DO - 10.6004/jnccn.2009.0061

M3 - Review article

C2 - 19878637

AN - SCOPUS:72149104327

SN - 1540-1405

VL - 7

SP - 908

EP - 942

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Multiple myeloma

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this